LEADERSHIP TEAM

Robert has over 40 years of experience in academic medicine, being a recognised leader in biomedical research, management and governance. He has held various leadership roles in a range of hospitals and laboratories. Prior roles also include his Presidency of the Academy of Medical Sciences, Membership of the UK Council for Science and Technology, and Chairmanship of the UK MHRA Clinical Trials Expert Advisory Group. Robert currently sits on the Board of Directors at NHS England, Quell Therapeutics and SC1. In 2012, Robert was Knighted in the Queen’s Birthday Honours for his services to academic medicine.

Susan has over 25 years of finance experience in life sciences and investment banking, including as Managing Director of Equity Capital Markets at Citigroup Global Markets Limited and Managing Director at Torreya Partners LLC. Susan currently sits on the Board of Directors of several life science and technology companies including Scancell Holdings, Science Group and Exploristics. Susan is also an Advisor for Oxford Sciences Enterprises.

Gur has over 20 years of healthcare industry and finance experience and is currently a Partner at aMoon. Previously Gur held CEO roles at various private and public biotechnology companies, as well as roles in venture capital at Venrock and equity research at Piper Jaffray. Gur undertook his residency training in internal medicine at Mount Sinai Medical Center where he was Chief Resident.

Bob has practiced law in Los Angeles, CA for more than 40 years in the field of taxation and business law. As an entrepreneur, he has financed more than a dozen small companies including several involved in medical science. Bob currently sits on the Board of Directors of several biotechnology companies including Hibernation Therapeutics, Bioseal and ICL Therapeutics.

Peter serves as a Non Executive Director at MiNA, having previously served as its Chief Business Officer. Peter brings three decades of experience in the global pharmaceutical space. Peter is Group Chief Executive Officer of Biocon (BSE:532523). Prior to this Peter held multiple leadership roles in biopharmaceuticals including Chief Business Officer of MiNA and Chief Executive Officer of Sosei Heptares (TSE:4565). Prior to this Peter held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. Peter is also Non Executive Chairman of ILC Therapeutics and Non Executive Director of Indivior (LSE:INDV).

Robert joined MiNA as founding Chief Executive Officer in 2013. Robert has overseen MiNA’s growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners. During his tenure MiNA has established itself as the leader in saRNA therapeutics, attracting over $100m of funding. Prior to joining MiNA, Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.

Deya Corzo is Chief Medical Officer-in-residence at Roivant Sciences. Deya is an expert in drug development, clinical genetics and rare diseases with over two decades of experience in the biotechnology sector. Prior industry experience includes roles as Chief Medical Officer at Sigilon Therapeutics and Sojournix Inc., and senior R&D positions at uniQure and Genzyme Corporation overseeing clinical development programs for rare diseases. Deya is a practicing, board-certified clinical geneticists and pediatrician, as well as a faculty member at Harvard Medical School where she completed postdoctoral research and clinical training.

Nagy is a co-founder and previously Head of R&D of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.

Declan is Chief Medical Officer of Juvenescence, Chairman of Biohaven Pharmaceuticals and Non Executive Director of Portage Biotech. He has more than 30 years of pharmaceutical industry experience spanning numerous roles including Chief Medical Officer at Amarin Corporation and Senior Vice President and Head of World Development at Pfizer. Declan is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received his Medical degree from Glasgow University.

Antonin is currently Chief Executive Officer of Evox Therapeutics. Prior to this Antonin held several senior R&D leadership roles including Chief Scientific Officer of Ablynx, Chief Scientific Officer of Moderna Therapeutics and Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals. After completing his PhD in Immunology at Harvard University, Antonin was a research fellow at the Wellcome Trust Immunology Unit, University of Cambridge.

Hans is Principal of BioTD Strategies, LLC, where he advises biotechnology companies and life science investors on preclinical development strategy and evaluation of targeted drug delivery and RNA therapeutics programs and technologies. In addition, Hans is an Adjunct Associate Professor of Systems Pharmacology and Translational Therapeutics and Associate Director of The Center for Targeted Therapeutics and Translational Nanomedicine at the University of Pennsylvania. Previously, Hans held multiple roles in preclinical R&D at Merck & Co., Inc, most recently Distinguished Senior Investigator, RNA Therapeutics. Hans received his PhD in Biochemistry at the ETH Zurich and was a research fellow at Harvard Medical School.

John is Dean Emeritus of the Irell and Manella Graduate School of Biological Sciences and Co-Director of the Center for RNA Biology and Therapeutics at City of Hope’s Beckman Research Institute. He is a pioneer in the field of molecular genetics and in particular small RNA biology. John founded Calando Pharmaceuticals, a wholly owned subsidiary of Arrowhead Research Corporation, and is Scientific Co-Founder of Dicerna Pharmaceuticals. John is Co-Founder of MiNA Therapeutics. In recognition of his major contributions to the field, John was appointed Honorary Board Member of the Oligonucleotide Therapeutics Society.

Pål is Professor in Bioinformatics at the Norwegian University of Science and Technology at Trondheim. He develops and applies predictive computational models to gene regulation in a disease setting. Pål is Co-Founder of MiNA Therapeutics and Interagon AS.